MX2007002606A - Uso de un modulador del receptor selectivo a estrogeno para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos. - Google Patents

Uso de un modulador del receptor selectivo a estrogeno para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos.

Info

Publication number
MX2007002606A
MX2007002606A MX2007002606A MX2007002606A MX2007002606A MX 2007002606 A MX2007002606 A MX 2007002606A MX 2007002606 A MX2007002606 A MX 2007002606A MX 2007002606 A MX2007002606 A MX 2007002606A MX 2007002606 A MX2007002606 A MX 2007002606A
Authority
MX
Mexico
Prior art keywords
prevention
manufacture
treatment
pharmaceutical preparation
androgen deficiency
Prior art date
Application number
MX2007002606A
Other languages
English (en)
Inventor
Risto Lammintausta
Taru Blom
Janne Komi
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/fi
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of MX2007002606A publication Critical patent/MX2007002606A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion se refiere a un uso del modulador del receptor selectivo a estrogeno, o un isomero, mezcla de isomeros, metabolito o una sal farmaceuticamente aceptable del mismo para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos o enfermedades y trastornos ocasionados por la deficiencia de androgenos en un individuo macho.
MX2007002606A 2004-09-03 2005-07-20 Uso de un modulador del receptor selectivo a estrogeno para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos. MX2007002606A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
FI20041216A FI20041216A0 (fi) 2004-09-21 2004-09-21 Menetelmä androgeenivajeen hoitoon tai estoon
PCT/FI2005/000333 WO2006024689A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Publications (1)

Publication Number Publication Date
MX2007002606A true MX2007002606A (es) 2007-05-15

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002606A MX2007002606A (es) 2004-09-03 2005-07-20 Uso de un modulador del receptor selectivo a estrogeno para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos.

Country Status (10)

Country Link
EP (1) EP1786408A4 (es)
JP (1) JP2008511615A (es)
KR (1) KR20070059110A (es)
AU (1) AU2005279178A1 (es)
BR (1) BRPI0514701A (es)
CA (1) CA2578852A1 (es)
MX (1) MX2007002606A (es)
NO (1) NO20071160L (es)
RU (1) RU2007112114A (es)
WO (1) WO2006024689A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5363344B2 (ja) 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
JP6697467B2 (ja) 2014-12-29 2020-05-20 オロン エス．ピー．エー． オスペミフェン及びフィスペミフェンを調製するためのプロセス
WO2023175010A1 (fr) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Utilisation du bazedoxifene pour augmenter la survie musculaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
JP2003534375A (ja) * 2000-05-26 2003-11-18 フィッチ，ハリー 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
EA200400744A1 (ru) * 2001-11-29 2005-02-24 Джи Ти Икс, ИНК. Предупреждение и лечение остеопороза, вызванного депривацией андрогенов

Also Published As

Publication number Publication date
JP2008511615A (ja) 2008-04-17
BRPI0514701A (pt) 2008-06-24
RU2007112114A (ru) 2008-10-10
KR20070059110A (ko) 2007-06-11
EP1786408A4 (en) 2010-07-28
CA2578852A1 (en) 2006-03-09
AU2005279178A1 (en) 2006-03-09
WO2006024689A1 (en) 2006-03-09
NO20071160L (no) 2007-05-25
EP1786408A1 (en) 2007-05-23

Similar Documents

Publication Publication Date Title
WO2007025005A3 (en) Sustained release formulations of nalbuphine
MX2007002606A (es) Uso de un modulador del receptor selectivo a estrogeno para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos.
UA95447C2 (ru) Способ женской контрацепции
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
ZA200606173B (en) Effervescent oral opiate dosage form
EP1893182B8 (en) Oral dosage forms comprising progesterone and method of making and using the same
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
MX2010003550A (es) Forma de dosificacion intraoral con multiples porciones con propiedades organolepticas.
WO2005107810A3 (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
UA87515C2 (ru) Фармацевтическая композиция толтеродина с пролонгированным высвобождением
WO2012010669A3 (de) Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
MX2010003439A (es) Combinacion farmaceutica de aliskiren y valsartan.
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
NO20055187D0 (no) Fremgangsmate for behandling og forebygging av lavere urinkanal symptomer
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
WO2006046114A3 (en) Osmotic dosage forms providing ascending drug release, and processes for their preparation
WO2011047837A3 (de) Schmelzgranuliertes cinacalcet
WO2005092062A3 (en) Compounds for neurodegenerative disorders
EP1741430A4 (en) REMEDY FOR PSYCHO NEUROSIS DISEASES
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
TW200611686A (en) Effervescent oral opiate dosage forms and methods of administering opiates
BR0311209A (pt) Método de produção de unidades de dosagem farmacêuticas para administração oral, uso de etonogestrel, e, tablete